Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes with a HSP70 Peptide Aptamer

Journal of the National Cancer Institute

Volumn 108, Issue 3, 2016, Pages

  Gobbo, Jessica ^a,b,c   Marcion, Guillaume ^a,b   Cordonnier, Marine ^a,b   Dias, Alexandre M M ^a,b   Pernet, Nicolas ^a,b   Hammann, Arlette ^a,b   Richaud, Sarah ^a,b   Mjahed, Hajare ^a,b   Isambert, Nicolas ^a,b,c   Clausse, Victor ^a,b   Rébé, Cédric ^a,b,c   Bertaut, Aurélie ^c   Goussot, Vincent ^c   Lirussi, Frédéric ^a,b,d   Ghiringhelli, François ^a,b   De Thonel, Aurélie ^a,b   Fumoleau, Pierre ^c   Seigneuric, Renaud ^a,b,c   Garrido, Carmen ^a,b,e  

^a Institut Médical de Génétique et d Immunologie   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Georges Francois Leclerc Center   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e Equipe Labellisée Par la Ligue Nationale Contre le Cancer   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; HEAT SHOCK PROTEIN 70; PEPTIDE APTAMER; TOLL LIKE RECEPTOR 2; ANTINEOPLASTIC AGENT; TLR2 PROTEIN, HUMAN; TLR2 PROTEIN, MOUSE;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLAYER INTERFEROMETRY; BONE MARROW CELL; CANCER CELL LINE; CANCER PATIENT; CONTROLLED STUDY; ELECTRON MICROSCOPY; EXOSOME; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; INTERFEROMETRY; MOUSE; MYELOID DERIVED SUPPRESSIVE CELL; NANOPARTICLE TRACKING ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN; TUMOR IMMUNITY; ANIMAL; BREAST NEOPLASMS; C57BL MOUSE; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; LUNG NEOPLASMS; MALE; METABOLISM; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APTAMERS, PEPTIDE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; EXOSOMES; FEMALE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INTERFEROMETRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; SPLEEN; TOLL-LIKE RECEPTOR 2;

EID: 84962380809     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv330     Document Type: Article

References (34)

1. Liu Y, Wang L, Predina J, et al. Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity. Nat Med. 2013;19(9):1173-1177.
2. Chhabra A, Mukherji B. Death Receptor-Independent Activation-Induced Cell Death in Human Melanoma Antigen-Specific MHC Class I-Restricted TCR-Engineered CD4 T Cells. J Immunol. 2013;191(6):3471-3477.
3. Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402-1410.
4. Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91(8):493-502.
5. Nagaraj S, Collazo M, Corzo CA, et al. Regulatory myeloid suppressor cells in health and disease. Cancer Res. 2009;69(19):7503-7506.
6. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16(1):53-65.
7. Serafini P, De Santo C, Marigo I, et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2004;53(2):64-72.
8. Bobrie A, Théry C. Exosomes and communication between tumours and the immune system: are all exosomes equal? Biochem Soc Trans. 2013;41(1):263-267.
9. Ostrowski M, Carmo NB, Krumeich S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19-30; sup pp 1-13.
10. McLellan AD. Exosome release by primary B cells. Crit Rev Immunol. 2009;29(3):203-217.
11. Knight AM. Regulated release of B cell-derived exosomes: do differences in exosome release provide insight into different APC function for B cells and DC? Eur J Immunol. 2008;38(5):1186-1189.
12. Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Salivary gland epithelial cell exosomes: A source of autoantigenic ribonucleoproteins. Arthritis Rheum. 2005;52(5):1517-1521.
13. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009;9(8):581-593.
14. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
15. Peinado H, Ale?kovi? M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18(6):883-891.
16. Bobrie A, Colombo M, Raposo G, Théry C. Exosome secretion: molecular mechanisms and roles in immune responses. Traffic. 2011;12(12):1659-1668.
17. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. 2010;120(2):457-471.
18. Balaburski GM, Leu JI-J, Beeharry N, et al. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res. 2013;11(3):219-229.
19. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med. 2008;12(3):743-761.
20. Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332(2):275-285.
21. Multhoff G. Heat shock protein 70 (Hsp70): Membrane location, export and immunological relevance. Methods. 2007;43:229-237.
22. Stangl S, Gehrmann M, Riegger J, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A. 2011;108(2):733-738.
23. Rérole A-L, Gobbo J, De Thonel A, et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011;71(2):484-495.
24. Baines IC, Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov Today. 2006;11(7-8):334-341.
25. Seigneuric R, Gobbo J, Colas P, Garrido C. Targeting cancer with peptide aptamers. Oncotarget. 2011;2(7):557-561.
26. Stangl S, Themelis G, Friedrich L, et al. Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother Oncol. 2011;99(3):313-316.
27. Kapanadze T, Gamrekelashvili J, Ma C, et al. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. J Hepatol. 2013;59(5):1007-1013.
28. Xiang X, Liu Y, Zhuang X, et al. TLR2-mediated expansion of MDSCs is dependent on the source of tumor exosomes. Am J Pathol. 2010;177(4):1606-1610.
29. Chang Q, Bournazou E, Sansone P, et al. The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis. Neoplasia. 2013;15(7):848-862.
30. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63(15):4441-4449.
31. Hanahan D, Weinberg RA, Francisco S. The Hallmarks of Cancer Review University of California at San Francisco. Cell. 2000;100:57-70.
32. Rébé C, Végran F, Berger H, Ghiringhelli F. A key factor in tumor immunoescape. JAK-STAT 2013;2(1):e23010.
33. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Crosstalk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179(2):977-983.
34. Coles DJ, Rolfe BE, Boase NRB, Veedu RN, Thurecht KJ. Aptamer-targeted hyperbranched polymers: towards greater specificity for tumours in vivo. Chem Commun (Camb). 2013;49(37):3836-3838.